logo-loader
CytoDyn

Full interview: CytoDyn injects first breast cancer patient with its flagship therapy

CytoDyn Inc (OTCMKTS:CYDY) CEO Dr. Nader Pourhassan tells Proactive that biotech has injected its first patient, who has an aggressive type of breast cancer, with its leronlimab treatment.

Pourhassan explains the difference between this emergency investigational new drug (IND) circumstance versus its ongoing Phase 1b/2 clinical trial on leronlimab.

Quick facts: CytoDyn

Price: 0.3302 USD

Market: OTCMKTS
Market Cap: $128.2 m
Follow

NO INVESTMENT ADVICE

The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is...

In exchange for publishing services rendered by the Company on behalf of CytoDyn named herein, including the promotion by the Company of CytoDyn in any Content on the Site, the Company receives from said issuer...

FOR OUR FULL DISCLAIMER CLICK HERE

Watch

Full interview: CytoDyn sees 'strong result' in leronlimab dose escalation...

CytoDyn Inc (OTCMKTS:CYDY) CEO Dr Nader Pourhassan tells Proactive the biotech's HIV monotherapy dose escalating trial with its flagship drug leronlimab (PRO 140) topped expectations. Dr Pourhassan says patients receiving 525 mg achieved a 'strong result' with a 94% response rate. 

on 14/8/19

2 min read